Dr. Alain Algazi, MD

Dr. Algazi practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Algazi's NPI, 1821289794, was assigned on August 6, 2007. Dr. Algazi graduated from David Geffen School of Medicine at UCLA in 2004. Dr. Algazi holds California license A93703.

Dr. Algazi's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Algazi's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Algazi is also affiliated with UCSF Health Stanyan Hospital. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Algazi to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Algazi practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Algazi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Algazi is board certified in medical oncology by the American Board of Internal Medicine. Dr. Algazi is licensed in California.

Dmand AI lists chronic anemia and fluid and electrolyte imbalances among the conditions Dr. Algazi treats.

CMS data shows 836 Medicare services from Dr. Algazi across 5 procedure codes in 2024, for 214 Medicare patients. Medicare paid $82,261 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 214 Medicare patients who saw Dr. Algazi in 2024. The largest group is 65 to 74, with 103 patients. 72% of them have high blood pressure, and 62% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Algazi's median patient age at 72, with 33% women.

In 2024, Dr. Algazi wrote 305 Medicare Part D claims for 94 patients. 76% of them were for generic drugs. CMS names the drug for 127 of them, across 5 drugs with 11 or more claims each, at $1,772 in total drug cost. In 2023, CMS named 115 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Algazi for performance year 2024, reported as part of a group. Dr. Algazi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Algazi as offering telehealth.

Dmand AI links 64 papers to Dr. Algazi, published from 2010 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Melanoma, Antineoplastic Combined Chemotherapy Protocols and Skin Neoplasms. Dr. Algazi has published most often in Ann Oncol. Dr. Algazi's most frequent co-authors are Adil I. Daud, MD, Patrick Ha, MD and Sue Sun Yom, MD, PhD.

Dmand AI links Dr. Algazi to 9 clinical trials, 7 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Carcinoma, Squamous Cell. University of California, San Francisco sponsors the most, 3.

CMS Open Payments shows 26 general payments to Dr. Algazi from 8 drug and device companies from 2016 to 2024. Travel and lodging make up the largest share, 50% of the total. Genentech, Inc. paid the most, $11,611. It also lists 2 research payments totaling $44 from 2017 to 2018.

Dmand AI lists 1 award for Dr. Algazi, most recently CMS Stage 1 EHR in 2013.

Dr. Algazi graduated from David Geffen School of Medicine at UCLA in 2004.

Dr. Algazi is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.